Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Description

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

Conditions

Obesity, Hypertension

Talk to us

Study Overview

On this page

Study Details

Study overview

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Hershey

Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States, 17033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Men and women of all races
  • * Age 18 to 60 years
  • * Body mass index (BMI) between 30-40 kg/m2
  • * Hypertension defined as two or more seated blood pressure readings \>130/80 mmHg or use of antihypertensive medications
  • * Capable of giving informed consent
  • * Fluent in written and spoken English
  • * Satisfactory history and physical exam
  • * Age ≤ 17 or ≥ 61 years
  • * Taking more than two antihypertensive medications
  • * Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
  • * Pregnant or nursing women
  • * Women taking hormone replacement therapy within 6 months
  • * Decisional impairment
  • * Prisoners
  • * Alcohol or drug abuse
  • * Current smokers
  • * Highly trained athletes
  • * Subjects with \>5% weight change in the past 3 months
  • * Morbid obesity (BMI \> 40 kg/m2)
  • * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications)
  • * History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)
  • * History or presence of immunological or hematological disorders
  • * Impaired hepatic function \[aspartate aminotransferase (AST) or alanine transaminase (ALT) levels \>2 times upper limit of normal range\]
  • * Impaired renal function (serum creatinine \>2.0 mg/dl)
  • * Anemia
  • * Treatment with drugs increasing sympathetic activity \[e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants\]
  • * Treatment with phosphodiesterase-5 inhibitors
  • * Treatment with anticoagulants (e.g. warfarin)
  • * Treatment with chronic systemic glucocorticoid therapy (\>7 consecutive days in 1 month)
  • * Treatment with any investigational drug in the 1-month preceding the study
  • * Inability to give, or withdraw, informed consent

Ages Eligible for Study

18 Years to 60 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Milton S. Hershey Medical Center,

Amy Arnold, PhD, PRINCIPAL_INVESTIGATOR, Pennsylvania State University College of Medicine

Study Record Dates

2029-03